Your browser doesn't support javascript.
loading
The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial.
Marson, Anthony; Burnside, Girvan; Appleton, Richard; Smith, Dave; Leach, John Paul; Sills, Graeme; Tudur-Smith, Catrin; Plumpton, Catrin; Hughes, Dyfrig A; Williamson, Paula; Baker, Gus A; Balabanova, Silviya; Taylor, Claire; Brown, Richard; Hindley, Dan; Howell, Stephen; Maguire, Melissa; Mohanraj, Rajiv; Smith, Philip E.
Afiliación
  • Marson A; Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK. Electronic address: a.g.marson@liverpool.ac.uk.
  • Burnside G; Department of Health Data Science, University of Liverpool, Liverpool, UK.
  • Appleton R; The Roald Dahl EEG Unit, Alder Hey Children's Health Park, Liverpool, UK.
  • Smith D; The Walton Centre NHS Foundation Trust, Liverpool, UK.
  • Leach JP; School of Medicine, University of Glasgow, Glasgow, UK.
  • Sills G; Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK.
  • Tudur-Smith C; Department of Health Data Science, University of Liverpool, Liverpool, UK.
  • Plumpton C; Centre for Health Economics and Medicines Evaluation, Bangor University, Bangor, Wales, UK.
  • Hughes DA; Centre for Health Economics and Medicines Evaluation, Bangor University, Bangor, Wales, UK.
  • Williamson P; Department of Health Data Science, University of Liverpool, Liverpool, UK.
  • Baker GA; Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK.
  • Balabanova S; Liverpool Clinical Trials Centre, University of Liverpool, Liverpool, UK.
  • Taylor C; Liverpool Clinical Trials Centre, University of Liverpool, Liverpool, UK.
  • Brown R; Addenbrooke's Hospital NHS Foundation Trust, Cambridge, UK.
  • Hindley D; Bolton NHS Foundation Trust, Royal Bolton Hospital, Lancashire, UK.
  • Howell S; Department of Neurology, Royal Hallamshire Hospital, Sheffield, UK.
  • Maguire M; School of Medicine, University of Leeds, Leeds, UK.
  • Mohanraj R; Salford Royal NHS Foundation Trust, Manchester, UK.
  • Smith PE; The Alan Richens Epilepsy Unit, University Hospital of Wales, Cardiff, Wales, UK.
Lancet ; 397(10282): 1363-1374, 2021 04 10.
Article en En | MEDLINE | ID: mdl-33838757
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Resultado del Tratamiento / Análisis Costo-Beneficio / Epilepsias Parciales / Lamotrigina / Levetiracetam / Zonisamida / Anticonvulsivantes Tipo de estudio: Clinical_trials / Diagnostic_studies / Guideline / Health_economic_evaluation / Health_technology_assessment Límite: Adolescent / Adult / Aged / Child / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Año: 2021 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Resultado del Tratamiento / Análisis Costo-Beneficio / Epilepsias Parciales / Lamotrigina / Levetiracetam / Zonisamida / Anticonvulsivantes Tipo de estudio: Clinical_trials / Diagnostic_studies / Guideline / Health_economic_evaluation / Health_technology_assessment Límite: Adolescent / Adult / Aged / Child / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Año: 2021 Tipo del documento: Article